

Giorgio Inghirami

List of Publications by Citations

Source: <https://exaly.com/author-pdf/270689/giorgio-inghirami-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

168
papers

7,932
citations

46
h-index

87
g-index

177
ext. papers

9,920
ext. citations

8.4
avg, IF

5.57
L-index

#	Paper	IF	Citations
168	DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. <i>Nature Communications</i> , 2017 , 8, 15618	17.4	770
167	The anaplastic lymphoma kinase in the pathogenesis of cancer. <i>Nature Reviews Cancer</i> , 2008 , 8, 11-23	31.3	673
166	Stromal contribution to the colorectal cancer transcriptome. <i>Nature Genetics</i> , 2015 , 47, 312-9	36.3	407
165	Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. <i>Nature Medicine</i> , 2005 , 11, 623-9	50.5	359
164	Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. <i>Oncogene</i> , 2002 , 21, 1038-47	9.2	311
163	The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. <i>Journal of Experimental Medicine</i> , 2012 , 209, 1537-51	16.6	289
162	Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. <i>Cancer Cell</i> , 2015 , 27, 516-32	24.3	283
161	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2014 , 123, 1293-6	2.2	255
160	Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. <i>Blood</i> , 2015 , 125, 1061-72	2.2	206
159	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. <i>Clinical Cancer Research</i> , 2015 , 21, 1628-38	12.9	188
158	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016 , 29, 574-586	24.3	154
157	Patient derived organoids to model rare prostate cancer phenotypes. <i>Nature Communications</i> , 2018 , 9, 2404	17.4	149
156	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , 2014 , 15, 730-7	21.7	135
155	Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death. <i>Nature</i> , 2019 , 567, 118-122	50.4	130
154	Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1583-90	2.2	129
153	Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 125, 111-23	2.2	117
152	New and old functions of STAT3: a pivotal target for individualized treatment of cancer. <i>Cell Cycle</i> , 2005 , 4, 1131-3	4.7	107

151	Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3019-25 ²	2.2	102
150	The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. <i>Nature Medicine</i> , 2008 , 14, 676-80	50.5	93
149	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 652-60	5.1	92
148	The genetics of nodal marginal zone lymphoma. <i>Blood</i> , 2016 , 128, 1362-73	2.2	88
147	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. <i>Blood</i> , 2019 , 133, 1664-1676	2.2	87
146	PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. <i>Nature Medicine</i> , 2012 , 18, 1699-704	50.5	85
145	Epigenomic evolution in diffuse large B-cell lymphomas. <i>Nature Communications</i> , 2015 , 6, 6921	17.4	81
144	The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling. <i>Nature Cell Biology</i> , 2015 , 17, 81-94	23.4	81
143	Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. <i>Blood</i> , 2012 , 120, 1274-81	2.2	80
142	STAT3: a multifaceted oncogene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 10151-10152	11.5	80
141	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. <i>Cancer Discovery</i> , 2018 , 8, 1632-1653	24.4	77
140	Molecular Checkpoint Decisions Made by Subverted Vascular Niche Transform Indolent Tumor Cells into Chemoresistant Cancer Stem Cells. <i>Cancer Cell</i> , 2017 , 31, 110-126	24.3	76
139	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. <i>Blood</i> , 2013 , 122, 2683-93	2.2	75
138	The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. <i>Cancer Research</i> , 2007 , 67, 4278-86	10.1	75
137	NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. <i>Cancer Research</i> , 2009 , 69, 8611-9	10.1	73
136	MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. <i>Blood</i> , 2013 , 122, 2083-92	2.2	69
135	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 764-769	11.5	67
134	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. <i>Cancer Research</i> , 2017 , 77, e62-e66	10.1	65

133	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. <i>Blood</i> , 2016 , 127, 221-32	2.2	65
132	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. <i>Nature Medicine</i> , 2020 , 26, 1114-1124	50.5	63
131	Integrin $\alpha 5 \beta 1$ acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. <i>Blood</i> , 2015 , 125, 841-51	2.2	61
130	CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 670-9	6.1	60
129	THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. <i>Nature Communications</i> , 2017 , 8, 14290	17.4	58
128	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. <i>Cancer Discovery</i> , 2020 , 10, 440-459	24.4	54
127	Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. <i>Blood</i> , 2016 , 127, 858-68	2.2	54
126	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. <i>Nature Communications</i> , 2018 , 9, 2024	17.4	54
125	Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer. <i>BMC Systems Biology</i> , 2014 , 8, 97	3.5	47
124	The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. <i>Cancer Research</i> , 2008 , 68, 8899-907	10.1	47
123	Three-dimensional chromatin landscapes in T cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2020 , 52, 388-400	36.3	46
122	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. <i>Nature Immunology</i> , 2019 , 20, 86-96	19.1	39
121	CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	37
120	Molecular features of primary mediastinal B-cell lymphoma: involvement of p16INK4A, p53 and c-myc. <i>British Journal of Haematology</i> , 1999 , 107, 106-13	4.5	36
119	The Influence of Tissue Ischemia Time on RNA Integrity and Patient-Derived Xenografts (PDX) Engraftment Rate in a Non-Small Cell Lung Cancer (NSCLC) Biobank. <i>PLoS ONE</i> , 2016 , 11, e0145100	3.7	36
118	A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. <i>Blood</i> , 2019 , 133, 1201-1204	2.2	35
117	AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. <i>Nature Communications</i> , 2018 , 9, 222	17.4	34
116	Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. <i>Blood Advances</i> , 2016 , 1, 47-61	7.8	33

115	Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4397-4412	15.9	33
114	Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications. <i>British Journal of Haematology</i> , 2018 , 181, 642-652	4.5	31
113	PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. <i>Blood</i> , 2018 , 132, 2026-2039	2.2	31
112	OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. <i>Oncotarget</i> , 2016 , 7, 84675-84687	3.3	31
111	Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. <i>Molecular Therapy - Nucleic Acids</i> , 2018 , 13, 334-346	10.7	31
110	Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2020 , 30, 755-770.e6	10.6	30
109	Anaplastic large-cell lymphoma. <i>Seminars in Diagnostic Pathology</i> , 2011 , 28, 190-201	4.3	30
108	Peripheral T cell lymphomas: from the bench to the clinic. <i>Nature Reviews Cancer</i> , 2020 , 20, 323-342	31.3	29
107	Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications. <i>Cellular and Molecular Bioengineering</i> , 2014 , 7, 394-408	3.9	29
106	Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018 , 26, 383-387	1.9	28
105	Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. <i>Cancer Discovery</i> , 2021 , 11, 1468-1489	24.4	27
104	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. <i>Cancer Immunology Research</i> , 2015 , 3, 1333-1343	12.5	25
103	Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications. <i>Immunological Reviews</i> , 2015 , 263, 124-59	11.3	25
102	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. <i>Leukemia</i> , 2019 , 33, 696-709	10.7	25
101	Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. <i>Life Science Alliance</i> , 2021 , 4,	5.8	25
100	N- and K-ras oncogenes in plasma cell dyscrasias. <i>Leukemia and Lymphoma</i> , 1994 , 15, 17-20	1.9	23
99	The heterogeneous landscape of ALK negative ALCL. <i>Oncotarget</i> , 2017 , 8, 18525-18536	3.3	22
98	Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma. <i>American Journal of Pathology</i> , 2020 , 190, 2-10	5.8	22

97	The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3. <i>Cancer Research</i> , 2019 , 79, 3076-3087	10.1	20
96	Pathogenesis of Peripheral T Cell Lymphoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018 , 13, 293-320	34	20
95	T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. <i>Blood Advances</i> , 2020 , 4, 4640-4647	7.8	20
94	Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 105	22.4	18
93	Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq data. <i>Scientific Reports</i> , 2017 , 7, 11301	4.9	18
92	Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. <i>Oncotarget</i> , 2016 , 7, 79637-79653	3.3	18
91	Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1626-1631	1.9	16
90	Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2838-2840	1.9	16
89	Anaplastic lymphoma kinase inhibitors. <i>Current Opinion in Pharmacology</i> , 2015 , 23, 39-44	5.1	14
88	IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas. <i>Cancers</i> , 2018 , 10,	6.6	14
87	Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma. <i>Oncotarget</i> , 2016 , 7, 41913-41928	3.3	14
86	Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition. <i>Human Gene Therapy</i> , 2015 , 26, 220-31	4.8	13
85	Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. <i>Haematologica</i> , 2020 , 105, 2432-2439	6.6	12
84	Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis. <i>Experimental and Molecular Pathology</i> , 2017 , 102, 276-279	4.4	11
83	Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 4019-4019	2.2	11
82	Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. <i>Modern Pathology</i> , 2020 , 33, 179-187	9.8	11
81	Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. <i>Haematologica</i> , 2021 , 106, 1693-1704	6.6	11
80	Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas. <i>European Journal of Cardio-thoracic Surgery</i> , 2017 , 51, 680-688	3	10

79	Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma. <i>Human Pathology</i> , 2018 , 75, 167-178	3.7	9
78	Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. <i>Oncolimmunology</i> , 2018 , 7, e1341032	7.2	9
77	Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas. <i>Blood</i> , 2018 , 132, 2922-2922	2.2	9
76	A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma. <i>Blood</i> , 2016 , 128, 150-150	2.2	9
75	Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities. <i>Oncotarget</i> , 2016 , 7, 25064-86	3.3	9
74	Repurposing dasatinib for diffuse large B cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 16981-16986	11.5	8
73	Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research. <i>Cancers</i> , 2020 , 12,	6.6	8
72	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. <i>American Journal of Hematology</i> , 2019 , 94, 628-634	7.1	7
71	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. <i>Blood</i> , 2014 , 124, 4417-4417	2.2	7
70	The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes. <i>Blood</i> , 2014 , 124, 705-705	2.2	7
69	Refractory T-Cell Prolymphocytic Leukemia with JAK3 Mutation: In Vitro and Clinical Synergy of Tofacitinib and Ruxolitinib. <i>Blood</i> , 2015 , 126, 5486-5486	2.2	7
68	Longitudinal immune profiling of mild and severe COVID-19 reveals innate and adaptive immune dysfunction and provides an early prediction tool for clinical progression 2020 ,		7
67	Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. <i>Blood</i> , 2021 , 138, 213-220	2.2	7
66	The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK anaplastic large cell lymphoma by regulating the DNA helicase HELLS. <i>Leukemia</i> , 2020 , 34, 2964-2980	10.7	6
65	Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. <i>Blood</i> , 2021 , 137, 788-800	2.2	6
64	Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling. <i>Blood</i> , 2019 , 134, 656-656	2.2	5
63	Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2021 ,	2.2	5
62	Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	5

61	induces NF- κ B signaling-driven peripheral T cell lymphoma. <i>Nature Cancer</i> , 2021 , 2, 98-113	15.4	5
60	The DNA-helicase HELLS drives ALK ALCL proliferation by the transcriptional control of a cytokinesis-related program. <i>Cell Death and Disease</i> , 2021 , 12, 130	9.8	5
59	Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment. <i>Modern Pathology</i> , 2020 , 33, 1380-1388	9.8	4
58	Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment.. <i>Frontiers in Immunology</i> , 2021 , 12, 809937	8.4	4
57	Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. <i>Blood</i> , 2021 ,	2.2	4
56	A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. <i>Cancers</i> , 2020 , 12,	6.6	3
55	Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study. <i>British Journal of Haematology</i> , 2018 , 182, 453-456	4.5	3
54	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. <i>Blood</i> , 2018 , 132, 1702-1702	2.2	3
53	The Brd-Inhibitor OTX015 Is Active in Pre-Clinical Models of Mature B-Cell Lymphoid Tumors. <i>Blood</i> , 2012 , 120, 1657-1657	2.2	3
52	Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531. <i>ELife</i> , 2020 , 9,	8.9	3
51	Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. <i>Cancer Research</i> , 2021 , 81, 5202-5216	10.1	3
50	PKC δ Inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. <i>Molecular Cell</i> , 2021 , 81, 4509-4526.e10	17.6	3
49	Transcriptional Analysis of Lennert Lymphoma Reveals a Unique Profile and Identifies Novel Therapeutic Targets. <i>Frontiers in Genetics</i> , 2019 , 10, 780	4.5	2
48	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018 , 132, 922-922.2	2.2	2
47	The Brd-Inhibitor OTX015 Shows Pre-Clinical Activity in Anaplastic Large T-Cell Lymphoma (ALCL). <i>Blood</i> , 2012 , 120, 4872-4872	2.2	2
46	Genetic Mechanisms of Immune Escape in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2014 , 124, 1692-1692	2.2	2
45	Specification of fetal liver endothelial progenitors to functional zoned adult sinusoids requires c-Maf induction.. <i>Cell Stem Cell</i> , 2022 ,	18	2
44	Are we ready to take full advantage of patient-derived tumor xenograft models?. <i>Hematological Oncology</i> , 2018 , 36, 24-27	1.3	1

43	Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. <i>British Journal of Haematology</i> , 2000 , 111, 263-271	4.5	1
42	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , 2018 , 132, 2962-2962	2.2	1
41	Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. <i>Blood</i> , 2016 , 128, 4096-4096	2.2	1
40	Novel Long Non Coding RNA Blackmamba Is Associated to ALK- anaplastic Large Cell Lymphoma. <i>Blood</i> , 2016 , 128, 461-461	2.2	1
39	Anaplastic lymphoma kinase: activating mechanisms and signaling pathways. <i>Frontiers in Bioscience - Scholar</i> , 2015 , 7, 283-305	2.4	1
38	JAK-STAT in lymphoproliferative disorders. <i>Oncoscience</i> , 2015 , 2, 737-8	0.8	1
37	Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma. <i>Scientific Reports</i> , 2020 , 10, 13094	4.9	1
36	Transposable elements: The enemies within. <i>Experimental Hematology</i> , 2016 , 44, 913-6	3.1	1
35	Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways. <i>European Journal of Cancer</i> , 2021 , 144, 17-30	7.5	1
34	Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. <i>Frontiers in Oncology</i> , 2021 , 11, 701318	5.3	1
33	Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking. <i>ELife</i> , 2021 , 10,	8.9	1
32	Metabolic and immune markers for precise monitoring of COVID-19 severity and treatment		1
31	Shared Genomic Alterations in Patients with Co-Existing Myeloproliferative Neoplasms and Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 2776-2776	2.2	0
30	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. <i>Blood</i> , 2021 , 138, 1326-1326	2.1	0
29	High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study. <i>Blood</i> , 2021 , 138, 138-138	2.2	0
28	Cell cycle inhibition to target the Evolution of urothelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS606-TPS606	2.2	0
27	XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells. <i>Blood</i> , 2020 , 136, 18-18	2.2	
26	Dynamic Immune Surveillance in Durable Clinical Response to Combined BTK and BCL2 Inhibition in MCL at Longitudinal Single-Cell Resolution. <i>Blood</i> , 2021 , 138, 1323-1323	2.2	

- 25 Diffuse Large B Cell Pdx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents. *Blood*, **2021**, 138, 2406-2406 2.2
- 24 Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens. *Blood*, **2021**, 138, 865-865 2.2
- 23 HHV-6 in the Lymphoma Microenvironment: Both Chicken and Egg?. *Blood*, **2021**, 138, 1377-1377 2.2
- 22 FOXO1 Dependent Transcription Network Is a Targetable Vulnerability of Mantle Cell Lymphoma. *Blood*, **2021**, 138, 30-30 2.2
- 21 A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments. *Blood*, **2021**, 138, 704-704 2.2
- 20 519. Immune responses and COVID-19 severity. *Open Forum Infectious Diseases*, **2020**, 7, S325-S325 1
- 19 HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas. *Blood*, **2017**, 130, 645-645 2.2
- 18 Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma. *Blood*, **2018**, 132, 1640-1640 2.2
- 17 A Clinical Review of the Co-Occurrence of Myeloproliferative and Lymphoproliferative Neoplasms. *Blood*, **2018**, 132, 4285-4285 2.2
- 16 Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth. *Blood*, **2018**, 132, 2854-2854 2.2
- 15 Mapping MALT1 Signaling Connectivity Unveils Novel B-Cell Feedback Mechanisms Directing Assembly of Potent Anti-Lymphoma Regimens. *Blood*, **2019**, 134, 173-173 2.2
- 14 Heterogeneous Genetic Alterations and Novel Pathogenic Pathways in Relapsed DLBCL Revealed By Whole Exome Sequencing. *Blood*, **2019**, 134, 2770-2770 2.2
- 13 The DNA Helicase Hells Is a New Unconventional Player in ALK- Anaplastic Large Cell Lymphoma Biology. *Blood*, **2019**, 134, 1477-1477 2.2
- 12 Integrin $\alpha\beta$ Transduces Survival and Angiogenic Signals to T Cell Lymphomas and Is a Therapeutic Target. *Blood*, **2014**, 124, 510-510 2.2
- 11 Identification of a New Subclass of ALK Negative Anaplastic Large Cell Lymphoma Expressing Aberrant Levels of ERBB4 Transcripts. *Blood*, **2014**, 124, 1679-1679 2.2
- 10 Convergent Mutations and New Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. *Blood*, **2014**, 124, 781-781 2.2
- 9 Extracellular Nicotinamide Phosphoribosyltransferase (NAMPT) Shapes the CLL Microenvironment Promoting Macrophage M2 Polarization Via a Non-Enzymatic Mechanism. *Blood*, **2014**, 124, 3316-3316 2.2
- 8 Assessment of T-Cell Receptor Repertoire and Clonal Expansion in Peripheral T-Cell Lymphoma Using RNA-Seq Data. *Blood*, **2015**, 126, 1451-1451 2.2

- 7 The Pro-Tumorigenic Vascular Niche Sustains the T-Cell Acute Lymphoblastic Leukemia Phenotype and Fosters Resistance to Therapy. *Blood*, **2016**, 128, 279-279 2.2
- 6 VAV1 Activating Mutations and Translocations in Peripheral T-Cell Lymphomas. *Blood*, **2016**, 128, 2741-2741
- 5 Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia.. *Blood*, **2012**, 120, 2657-2657 2.2
- 4 The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia. *Blood*, **2012**, 120, 1778-1778 2.2
- 3 Genetic Factors Predicting The Response To BET Bromodomain Inhibitors In Lymphoma Lead To New Synergistic Combinations. *Blood*, **2013**, 122, 3070-3070 2.2
- 2 Cytoskeleton Dynamics in Peripheral T Cell Lymphomas: An Intricate Network Sustaining Lymphomagenesis. *Frontiers in Oncology*, **2021**, 11, 643620 5.3
- 1 In Vivo and Ex Vivo Patient-Derived Tumor Xenograft Models of Lymphoma for Drug Discovery. *Current Protocols*, **2021**, 1, e96